Bispecific Antibodies Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032
CHAPTER 1. Industry Overview of Bispecific Antibodies Market
1.1. Definition and Scope
1.1.1. Definition of Bispecific Antibodies
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Bispecific Antibodies Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Bispecific Antibodies Market By Drug Type
1.2.3. Bispecific Antibodies Market By Indication
1.2.4. Bispecific Antibodies Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Source
2.2.2. Primary Source
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Bispecific Antibodies Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Bispecific Antibodies Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Price Trend of Key Raw Material
3.8.1. Raw Material Suppliers
3.8.2. Proportion of Manufacturing Cost Structure
3.8.2.1. Raw Material
3.8.2.2. Labor Cost
3.8.2.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2022
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2022
4.2. R&D Status of Major Manufacturers in 2022
CHAPTER 5. Bispecific Antibodies Market By Drug Type
5.1. Introduction
5.2. Bispecific Antibodies Revenue By Drug Type
5.2.1. Bispecific Antibodies Revenue (USD Million) and Forecast, By Drug Type, 2020-2032
5.2.2. Blinatumomab
5.2.2.1. BlinatumomabMarket Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.3. Duligotumab
5.2.3.1. Duligotumab Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.4. Catumaxomab
5.2.4.1. Catumaxomab Market Revenue (USD Million) and Growth Rate (%), 2020-2032
5.2.5. Others
5.2.5.1. Others Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 6. Bispecific Antibodies Market By Indication
6.1. Introduction
6.2. Bispecific Antibodies Revenue By Indication
6.2.1. Bispecific Antibodies Revenue (USD Million) and Forecast, By Indication, 2020-2032
6.2.2. Cancer
6.2.2.1. Cancer Market Revenue (USD Million) and Growth Rate (%), 2020-2032
6.2.3. Inflammatory & Autoimmune Disorder
6.2.3.1. Inflammatory & Autoimmune Disorder Market Revenue (USD Million) and Growth Rate (%), 2020-2032
6.2.4. Others
6.2.4.1. Others Market Revenue (USD Million) and Growth Rate (%), 2020-2032
CHAPTER 7. North America Bispecific Antibodies Market By Country
7.1. North America Bispecific Antibodies Market Overview
7.2. U.S.
7.2.1. U.S. Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
7.2.2. U.S. Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
7.3. Canada
7.3.1. Canada Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
7.3.2. Canada Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
7.4. North America PEST Analysis
CHAPTER 8. Europe Bispecific Antibodies Market By Country
8.1. Europe Bispecific Antibodies Market Overview
8.2. U.K.
8.2.1. U.K. Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
8.2.2. U.K. Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
8.3. Germany
8.3.1. Germany Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
8.3.2. Germany Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
8.4. France
8.4.1. France Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
8.4.2. France Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
8.5. Spain
8.5.1. Spain Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
8.5.2. Spain Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
8.6. Rest of Europe
8.6.1. Rest of Europe Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
8.6.2. Rest of Europe Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
8.7. Europe PEST Analysis
CHAPTER 9. Asia Pacific Bispecific Antibodies Market By Country
9.1. Asia Pacific Bispecific Antibodies Market Overview
9.2. China
9.2.1. China Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
9.2.2. China Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
9.3. Japan
9.3.1. Japan Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
9.3.2. Japan Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
9.4. India
9.4.1. India Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
9.4.2. India Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
9.5. Australia
9.5.1. Australia Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
9.5.2. Australia Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
9.6. South Korea
9.6.1. South Korea Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
9.6.2. South Korea Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
9.7. Rest of Asia-Pacific
9.7.1. Rest of Asia-Pacific Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
9.7.2. Rest of Asia-Pacific Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
9.8. Asia Pacific PEST Analysis
CHAPTER 10. Latin America Bispecific Antibodies Market By Country
10.1. Latin America Bispecific Antibodies Market Overview
10.2. Brazil
10.2.1. Brazil Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
10.2.2. Brazil Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
10.3. Mexico
10.3.1. Mexico Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
10.3.2. Mexico Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
10.4. Rest of Latin America
10.4.1. Rest of Latin America Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
10.4.2. Rest of Latin America Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
10.5. Latin America PEST Analysis
CHAPTER 11. Middle East & Africa Bispecific Antibodies Market By Country
11.1. Middle East & Africa Bispecific Antibodies Market Overview
11.2. GCC
11.2.1. GCC Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
11.2.2. GCC Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
11.3. South Africa
11.3.1. South Africa Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
11.3.2. South Africa Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
11.4. Rest of Middle East & Africa
11.4.1. Rest of Middle East & Africa Bispecific Antibodies Revenue (USD Million) and Forecast By Drug Type, 2020-2032
11.4.2. Rest of Middle East & Africa Bispecific Antibodies Revenue (USD Million) and Forecast By Indication, 2020-2032
11.5. Middle East & Africa PEST Analysis
CHAPTER 12. Player Analysis Of Bispecific Antibodies Market
12.1. Bispecific Antibodies Market Company Share Analysis
12.2. Competition Matrix
12.2.1. Competitive Benchmarking Of Key Players By Price, Presence, Market Share, And R&D Investment
12.2.2. New Product Launches and Product Enhancements
12.2.3. Mergers And Acquisition In Global Bispecific Antibodies Market
12.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 13. Company Profile
13.1. Regeneron Pharmaceuticals, Inc.
13.1.1. Company Snapshot
13.1.2. Business Overview
13.1.3. Financial Overview
13.1.3.1. Revenue (USD Million), 2022
13.1.3.2. Regeneron Pharmaceuticals, Inc. 2022 Bispecific Antibodies Business Regional Distribution
13.1.4. Product/Service and Specification
13.1.5. Recent Developments & Business Strategy
13.2. Amgen Inc.
13.3. Roche Holding AG
13.4. Genentech, Inc.
13.5. Novartis AG
13.6. Pfizer Inc.
13.7. Merck & Co., Inc.
13.8. Eli Lilly and Company
13.9. Abbvie Inc.
13.10. Jounce Therapeutics, Inc.
13.11. MacroGenics, Inc.
13.12. Xencor, Inc.
Frequently Asked Questions
What was the market size of the global bispecific antibodies in 2022?
The market size of bispecific antibodies was USD 554 Million in 2022.
What is the CAGR of the global bispecific antibodies market from 2023 to 2032?
The CAGR of bispecific antibodies is 7.1% during the analysis period of 2023 to 2032.
Which are the key players in the bispecific antibodies market?
The key players operating in the global market are including Regeneron Pharmaceuticals, Inc., Amgen Inc., Roche Holding AG, Genentech, Inc., Novartis AG, Pfizer Inc., Merck & Co., Inc., Eli Lilly and Company, Abbvie Inc., Jounce Therapeutics, Inc., MacroGenics, Inc., and Xencor, Inc.
Which region dominated the global bispecific antibodies market share?
North America held the dominating position in bispecific antibodies industry during the analysis period of 2023 to 2032.
Which region registered fastest CAGR from 2023 to 2032?
Asia-Pacific region exhibited fastest growing CAGR for market of bispecific antibodies during the analysis period of 2023 to 2032.
What are the current trends and dynamics in the global bispecific antibodies industry?
The current trends and dynamics in the bispecific antibodies market growth include growing demand for targeted and personalized therapies, potential to improve treatment outcomes in cancer and other diseases, and advancements in antibody engineering and technology.
Which drug type held the maximum share in 2022?
The catumaxomab drug type held the maximum share of the bispecific antibodies industry.
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
